Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions
Tóm tắt
The authors sought to evaluate whether the reacquisition of images 3 h after administration of radiotracer improves the sensitivity of fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography ([18F]-FDG PET/CT) in patients with suspicious breast lesions. Forty-eight patients with 59 breast lesions underwent an [18F]-FDG PET/CT study in the prone position with a dual-time-point acquisition performed in the early phase 1 h after FDG administration (PET-1) and in the delayed phase 3 h after FDG administration (PET-2). Both examinations were evaluated qualitatively and semiquantitatively with calculation of the mean percentage variation of the standard uptake values (Δ% SUVmax) between PET-1 and PET-2. All lesions with an SUVmax ≥2.5 at PET-1 or a reduction in SUV between PET-1 and PET-2 were considered benign. The definitive histopathological diagnosis was available for all patients included in the study. The dual-time-point acquisition of [18F]-FDG PET/CT displayed an accuracy of 85% for lesions with an SUVmax ≥2.5 and/or positive Δ% SUVmax, with sensitivity and specificity values of 81% and 100% compared with 69%, 63% (both p<0.001) and 100% (p=n.s.), respectively, for the single-time-point acquisition. Malignant lesions showed an increase in FDG uptake between PET-1 and PET-2, with a Δ% SUVmax of 10±7 (p<0.04). In contrast, benign lesions showed a decrease in SUV between PET-1 and PET-2, with aΔ% SUVmax of −21±7 (p<0.001). The delayed repeat acquisition of PET images improves the accuracy of [18F]-FDG PET/CT in patients with suspicious breast lesions with respect to the single-time-point acquisition. In addition, malignant breast lesions displayed an increase in FDG uptake over time, whereas benign lesions showed a reduction. These variations in FDG uptake between PET-1 and PET-2 are a reliable parameter that can be used for differentiating between benign and malignant breast lesions.
Tài liệu tham khảo
Jemal A, Siegel R, Ward E et al (2007) Cancer statistics. CA Cancer J Clin 57:43–66
Schirrmeister H, Kuhn T, Guhlmann A et al (2001) Fluorine-18-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28:351–358
Eubank WB, Mankoff DA (2005) Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35:84–99
Matthies A, Hicheson M, Cuchiara A, Alavi A (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875
Kumar R, Loving VA, Chauhan A et al (2005) Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 46:1819–1824
Mavi A, Urhan M, Yu JQ et al (2006) Dual Time point 18F-FDG-PET imaging detects breast cancers with high sensitivity and correlates well with histologic subtypes. J Nucl Med 47:1440–1446
American College of Radiology (1995) Breast imaging reporting and data system (BI-RADS). American College of Radiology, Reston
Kennedy BJ (ed) (1992) Manual for the staging of cancer. Lippincott, Philadelphia
Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer correlation with biological and clinical prognostic parameters. Eur J Nucl Med Imaging 29:1317–1323
Lowe VJ, Fletcher JW, Gobar L et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075–1084
Dewan NA, Gupta NC, Redepenning LS et al (1993) Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 104:997–1002
Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point FDG PET imaging for differentiating malignant form inflammatory processes. J Nucl Med 42:1412–1417
Hustinx R, Smith RJ, Benard F et al (1999) Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26:1345–1348
Koyama K, Okamura T, Kawabe J et al (2002) The usefulness of FDG-PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 16:169–176
Torizuka T, Tamaki N, Inokuma T et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med 36:1811–1817
Nishiyama Y, Yamamoto Y, Monden T et al (2005) Evaluation of delayed additional FDG-PET imaging in patients with pancreatic tumour. Nucl Med Comm 26:895–901
Avril N, Rosè CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502
Kumar R, Chauhan A, Zhuang H et al (2006) Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography: variations with age, breast density, and menopausal status. Mol Imaging Biol 8:355–362
Hellwig D, Graeter TP, Ukena D et al (2007) 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense ? J Nucl Med 48:1761–1766
Murthy K, Aznar M, Thompson CJ et al (2000) Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 41:1851–1858
Tafra L (2007) Positron emission tomography (PET) and mammography (PEM) for breast cancer: importance to surgeons. Ann Surg Oncol 14:3–13
Weinberg IN, Beylin D, Zavarzin V et al (2005) Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 4:55–60